相关实验视频

Updated: Jul 10, 2025

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

根据先前的生物暴露,对17A型干白素抑制剂的反应:丹麦全国性研究

Nikolai Loft¹, Alexander Egeberg², Daniel Isufi³

¹Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital, Hellerup, Denmark. nikolai.dyrberg.loft@regionh.dk.

Acta dermato-venereologica

|November 21, 2023

概括

之前接触过针对其他细胞因子的生物药物不会影响介素-17A抑制剂的有效性. 接受IL-17A抑制剂的患者表现出类似的牛皮区域和严重性指数 (PASI) ≤2个响应,而不考虑先前的生物治疗史.

科学领域:

皮肤病学皮肤病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

干白素-17A (IL-17A) 抑制剂对于治疗炎症状况至关重要.
之前的生物暴露,特别是其他细胞因子标对IL-17A抑制剂反应的影响尚未得到充分理解.

研究的目的:

评估先前暴露于IL-17A抑制剂是否会影响反应,与暴露于针对不同细胞因子的生物药物相比.
为了确定先前的生物治疗是否会影响IL-17A抑制剂 (如secukinumab或ixekizumab) 的疗效.

主要方法:

在DERMBIO注册中对用IL-17A抑制剂治疗的患者的分析.
以往暴露于IL-17A抑制剂的患者和暴露于其他生物药物的患者之间的响应率 (牛皮区域和严重性指数 (PASI) ≤2) 的比较.
在3,6个月和12个月使用二次 (χ2) 测试进行统计分析.

主要成果:

在3个月后的组之间没有观察到PASI ≤ 2响应率的显著差异 (54%对57%,p = 0.59).
在6个月 (70%对66%,p=0.42) 和12个月 (69%对60%,p=0.14) 发现了类似的响应率.
在所有评估时间点中,在两组中,达到PASI ≤ 2的受访者比例是可比的.

结论:

之前暴露于IL-17A抑制剂并没有减少相比暴露于其他细胞因子标的生物药物的反应.
之前的生物治疗的细胞因子标似乎没有影响对IL-17A抑制剂的临床反应.

更多相关视频

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Published on: October 25, 2024

相关概念视频

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...